TY - JOUR
T1 - Associations of maternal cardiovascular health in pregnancy with offspring cardiovascular health in early adolescence
AU - Perak, Amanda M.
AU - Lancki, Nicola
AU - Kuang, Alan
AU - Labarthe, Darwin R.
AU - Allen, Norrina B.
AU - Shah, Svati H.
AU - Lowe, Lynn P.
AU - Grobman, William A.
AU - Lawrence, Jean M.
AU - Lloyd-Jones, Donald M.
AU - Lowe, William L.
AU - Scholtens, Denise M.
N1 - Funding Information:
Translational Research Grants Initiative), and the American Heart Association (17SFRN33660752) during the conduct of the study and grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (K23HL145101) outside the submitted work. Dr Shah reported receiving grants from AstraZeneca, Eli Lilly and Company, and Verily Life Sciences outside the submitted work. Dr Lowe reported receiving grants from the NIH during the conduct of the study. Dr Lloyd-Jones reported receiving grants from the NIH during the conduct of the study. Dr Lowe Jr reported serving as co-investigator on a grant from the NIH that supported the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Follow-Up Study (FUS) (grant U01DK94830) and principal investigator of 2 additional NIH grants, which provided some of the data used in these analyses (grant R01DK095963: “Maternal Obesity and Gestational Diabetes: Impact on Metabolome” and R01DK117491: “Predicting Newborn and Childhood Adiposity: An Integrated Omics Approach”). Dr Scholtens reported receiving grants from the NIH to support the HAPO study during the conduct of the study. No other disclosures were reported.
Funding Information:
Funding/Support: The HAPO Study was funded by grants R01HD34242 and R01HD34243 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, with additional HAPO ancillary study data obtained through grants R01DK095963 and R01DK117491 from the National Institute of Diabetes and Digestive and Kidney Diseases. The HAPO Follow-Up Study was funded by grant 1U01DK094830 from the National Institute of Diabetes and Digestive and Kidney Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The ancillary cardiovascular health study was funded by a Dixon Translational Research Grant from the Northwestern University Clinical and Translational Sciences Institute and the Northwestern Memorial Foundation, an Eleanor Wood-Prince Grant from the Woman’s Board of Northwestern Memorial Hospital, and a subcontract under grant 17SFRN33660752 from the American Heart Association. The research reported in this article was supported, in part, by grant UL1TR001422 from the National Center for Advancing Translational Sciences, NIH. Dr Perak’s work was supported by grant K23HL145101 from the National Heart, Lung, and Blood Institute and a Pediatric Physician-Scientist Research Award from the Northwestern University Feinberg School of Medicine Department of Pediatrics. The authors’ work was also supported in part by grants 17SFRN33660752 (Dr Labarthe), 17SFRN33700101 (Drs Labarthe, Allen, and Lloyd-Jones), and 17SFRN33700155 (Dr Shah) from the American Heart Association. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Funding Information:
receiving grants from the Woman’s Board of Northwestern Memorial Hospital (Eleanor Wood-Prince Grant), the Dixon Family (Dixon
Publisher Copyright:
© 2021 American Medical Association. All rights reserved.
PY - 2021/2/16
Y1 - 2021/2/16
N2 - IMPORTANCE Pregnancy may be a key window to optimize cardiovascular health (CVH) for the mother and influence lifelong CVH for her child. OBJECTIVE To examine associations between maternal gestational CVH and offspring CVH. DESIGN, SETTING, AND PARTICIPANTS This cohort study used data from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study (examinations: July 2000-April 2006) and HAPO Follow-Up Study (examinations: February 2013-December 2016). The analyses included 2302 mother-child dyads, comprising 48%of HAPO Follow-Up Study participants, in an ancillary CVH study. Participants were from 9 field centers across the United States, Barbados, United Kingdom, China, Thailand, and Canada. EXPOSURES Maternal gestational CVH at a target of 28 weeks' gestation, based on 5 metrics: body mass index, blood pressure, total cholesterol level, glucose level, and smoking. Each metric was categorized as ideal, intermediate, or poor using pregnancy guidelines. Total CVH was categorized as follows: all ideal metrics, 1 or more intermediate (but 0 poor) metrics, 1 poor metric, or 2 or more poor metrics. MAIN OUTCOMES AND MEASURES Offspring CVH at ages 10 to 14 years, based on 4 metrics: body mass index, blood pressure, total cholesterol level, and glucose level. Total CVH was categorized as for mothers. RESULTS Among 2302 dyads, the mean (SD) ages were 29.6 (2.7) years for pregnant mothers and 11.3 (1.1) years for children. During pregnancy, the mean (SD) maternal CVH score was 8.6 (1.4) out of 10. As shown in the Table, 32.8%of pregnant mothers had all ideal metrics, whereas 6.0% had 2 or more poor metrics, and the distribution of CVH categories among offspring varied by maternal CVH category. In adjusted models, poorer maternal CVH categories (vs all ideal maternal metrics) were associated with higher relative risks for offspring to have 1 poor and 2 or more poor metrics (vs all ideal metrics). {table presented} Additional adjustment for categorical birth factors (eg, preeclampsia) did not fully explain these significant associations (eg, relative risk for association between 2 or more poor metrics among mothers during pregnancy and 2 or more poor metrics among offspring after adjustment for an extended set of birth factors, 6.23 [95%CI, 3.03-12.82]). CONCLUSIONS AND RELEVANCE In this multinational cohort, better maternal CVH at 28 weeks' gestation was significantly associated with better offspring CVH at ages 10 to 14 years.
AB - IMPORTANCE Pregnancy may be a key window to optimize cardiovascular health (CVH) for the mother and influence lifelong CVH for her child. OBJECTIVE To examine associations between maternal gestational CVH and offspring CVH. DESIGN, SETTING, AND PARTICIPANTS This cohort study used data from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study (examinations: July 2000-April 2006) and HAPO Follow-Up Study (examinations: February 2013-December 2016). The analyses included 2302 mother-child dyads, comprising 48%of HAPO Follow-Up Study participants, in an ancillary CVH study. Participants were from 9 field centers across the United States, Barbados, United Kingdom, China, Thailand, and Canada. EXPOSURES Maternal gestational CVH at a target of 28 weeks' gestation, based on 5 metrics: body mass index, blood pressure, total cholesterol level, glucose level, and smoking. Each metric was categorized as ideal, intermediate, or poor using pregnancy guidelines. Total CVH was categorized as follows: all ideal metrics, 1 or more intermediate (but 0 poor) metrics, 1 poor metric, or 2 or more poor metrics. MAIN OUTCOMES AND MEASURES Offspring CVH at ages 10 to 14 years, based on 4 metrics: body mass index, blood pressure, total cholesterol level, and glucose level. Total CVH was categorized as for mothers. RESULTS Among 2302 dyads, the mean (SD) ages were 29.6 (2.7) years for pregnant mothers and 11.3 (1.1) years for children. During pregnancy, the mean (SD) maternal CVH score was 8.6 (1.4) out of 10. As shown in the Table, 32.8%of pregnant mothers had all ideal metrics, whereas 6.0% had 2 or more poor metrics, and the distribution of CVH categories among offspring varied by maternal CVH category. In adjusted models, poorer maternal CVH categories (vs all ideal maternal metrics) were associated with higher relative risks for offspring to have 1 poor and 2 or more poor metrics (vs all ideal metrics). {table presented} Additional adjustment for categorical birth factors (eg, preeclampsia) did not fully explain these significant associations (eg, relative risk for association between 2 or more poor metrics among mothers during pregnancy and 2 or more poor metrics among offspring after adjustment for an extended set of birth factors, 6.23 [95%CI, 3.03-12.82]). CONCLUSIONS AND RELEVANCE In this multinational cohort, better maternal CVH at 28 weeks' gestation was significantly associated with better offspring CVH at ages 10 to 14 years.
UR - http://www.scopus.com/inward/record.url?scp=85100911565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100911565&partnerID=8YFLogxK
U2 - 10.1001/jama.2021.0247
DO - 10.1001/jama.2021.0247
M3 - Article
C2 - 33591345
AN - SCOPUS:85100911565
SN - 0098-7484
VL - 325
SP - 658
EP - 668
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 7
ER -